Various Regulatory Modes for Circadian Rhythmicity and Sexual Dimorphism in the Non-Neuronal Cardiac Cholinergic System
- 247 Downloads
Cardiomyocytes possess a non-neuronal cardiac cholinergic system (NNCCS) regulated by a positive feedback system; however, its other regulatory mechanisms remain to be elucidated, which include the epigenetic control or regulation by the female sex steroid, estrogen. Here, the NNCCS was shown to possess a circadian rhythm; its activity was upregulated in the light-off phase via histone acetyltransferase (HAT) activity and downregulated in the light-on phase. Disrupting the circadian rhythm altered the physiological choline acetyltransferase (ChAT) expression pattern. The NNCCS circadian rhythm may be regulated by miR-345, independently of HAT, causing decreased cardiac ChAT expression. Murine cardiac ChAT expression and ACh contents were increased more in female hearts than in male hearts. This upregulation was downregulated by treatment with the estrogen receptor antagonist tamoxifen, and in contrast, estrogen reciprocally regulated cardiac miR-345 expression. These results suggest that the NNCCS is regulated by the circadian rhythm and is affected by sexual dimorphism.
KeywordsAcetylcholine Non-neuronal cardiac cholinergic system Circadian rhythm miRNA Sexual dimorphism
This manuscript has been checked for language and edited by Cactus Communications Inc., Tokyo, Japan.
Compliance with Ethical Standards
The present study was approved by the ethical committee of Nippon Medical School (permission number 27-0003), and all procedures were performed in strict accordance with the recommendations set forth in the guidelines of the institution, Physiological Society of Japan and the ARRIVE guidelines.
Sources of Funding
The current study was supported mainly by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) (C) Grant Numbers 25460333 and 16K08560, and partly by the Smoking Research Foundation.
Conflict of Interest
The authors declare that they have no conflict of interest.
No human studies were carried out by the authors for this article.
- 3.Rocha-Resende, C., Roy, A., Resende, R., Ladeira, M. S., Lara, A., de Morais Gomes, E. R., Prado, V. F., Gros, R., Guatimosim, C., Prado, M. A., & Guatimosim, S. (2012). Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals. Journal of Molecular and Cellular Cardiology, 53, 206–216.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Kakinuma, Y., Tsuda, M., Okazaki, K., Akiyama, T., Arikawa, M., Noguchi, T., & Sato, T. (2013). Heart-specific overexpression of choline acetyltransferase gene protects murine heart against ischemia through hypoxia-inducible factor-1α-related defense mechanisms. Journal of the American Heart Association, 2, e004887.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Kakinuma, Y., Furihata, M., Akiyama, T., Arikawa, M., Handa, T., Katare, R. G., & Sato, T. (2010). Donepezil, an acetylcholinesterase inhibitor against Alzheimer’s dementia, promotes angiogenesis in an ischemic hindlimb model. Journal of Molecular and Cellular Cardiology, 48, 680–693.CrossRefPubMedGoogle Scholar
- 10.Kakinuma, Y., Ando, M., Kuwabara, M., Katare, R. G., Okudela, K., Kobayashi, M., & Sato, T. (2005). Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha. FEBS Letters, 579, 2111–2118.CrossRefPubMedGoogle Scholar
- 16.Oikawa, S., Kai, Y., Tsuda, M., Ohata, H., Mano, A., Mizoguchi, N., Sugama, S., Nemoto, T., Suzuki, K., Kurabayashi, A., Muramoto, K., Kaneda, M., & Kakinuma, Y. (2016). Non-neuronal cardiac cholinergic system influences CNS via the vagus nerve to acquire a stress-refractory propensity. Clinical Science (London, England), 130, 1913–1928.CrossRefGoogle Scholar
- 22.Srivastava, S. K., Bhardwaj, A., Arora, S., Tyagi, N., Singh, S., Andrews, J., McClellan, S., Wang, B., & Singh, A. P. (2015). MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and -independent pathways. British Journal of Cancer, 113, 660–668.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Schou, J. V., Rossi, S., Jensen, B. V., Nielsen, D. L., Pfeiffer, P., Høgdall, E., Yilmaz, M., Tejpar, S., Delorenzi, M., Kruhøffer, M., & Johansen, J. S. (2014). miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PloS One, 9, e99886.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Yan, L., Ge, H., Li, H., Lieber, S. C., Natividad, F., Resuello, R. R., Kim, S. J., Akeju, S., Sun, A., Loo, K., Peppas, A. P., Rossi, F., Lewandowski, E. D., Thomas, A. P., Vatner, S. F., & Vatner, D. E. (2004). Gender-specific proteomic alterations in glycolytic and mitochondrial pathways in aging monkey hearts. Journal of Molecular and Cellular Cardiology, 37, 921–929.CrossRefPubMedGoogle Scholar